OSAM
IBRX icon

O'Shaughnessy Asset Management’s ImmunityBio IBRX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,396
Closed -$14K – 1806
2021
Q3 		$14K Hold
1,396
– – ﹤0.01% 2064
2021
Q2 		$20K Hold
1,396
– – ﹤0.01% 1845
2021
Q1 		$33K Buy
1,396
+1,242
+806% +$32.2K ﹤0.01% 1526
2020
Q4 		$2K Buy
154
+111
+258% +$1.07K ﹤0.01% 1839
2020
Q3 		$0 Hold
43
– – ﹤0.01% 1923
2020
Q2 		$1K Buy
+43
New +$243 ﹤0.01% 1606

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

O'Shaughnessy Asset Management's IBRX Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of ImmunityBio (IBRX) in Q4 2021, closing a stake of 1,396 shares — an estimated $14K sold.

O'Shaughnessy Asset Management first reported a position in IBRX in Q2 2020 and held it in 6 quarters. The position peaked at $33K in Q1 2021. 141 funds tracked by Wall St. Rank hold IBRX as of Q4 2021.

  • O'Shaughnessy Asset Management reported no remaining ImmunityBio position as of Q4 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 1,396 ImmunityBio shares in Q4 2021, an estimated $14K.
  • O'Shaughnessy Asset Management first reported a position in ImmunityBio in Q2 2020 and held it in 6 quarters.
  • O'Shaughnessy Asset Management's ImmunityBio position peaked at $33K in Q1 2021.
  • 141 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.